SARS-CoV-2 Vaccination in the First Year After Hematopoietic Cell Transplant or Chimeric Antigen Receptor T-Cell Therapy: A Prospective, Multicenter, Observational Study.

MLA

Hill, Joshua A., et al. “SARS-CoV-2 Vaccination in the First Year After Hematopoietic Cell Transplant or Chimeric Antigen Receptor T-Cell Therapy: A Prospective, Multicenter, Observational Study.” Clinical Infectious Diseases, vol. 79, no. 2, Aug. 2024, pp. 542–54. EBSCOhost, https://doi.org/10.1093/cid/ciae291.

APA

Hill, J. A., Martens, M. J., Young, J.-A. H., Bhavsar, K., Kou, J., Chen, M., Lee, L. W., Baluch, A., Dhodapkar, M. V., Nakamura, R., Peyton, K., Howard, D. S., Ibrahim, U., Shahid, Z., Armistead, P., Westervelt, P., McCarty, J., McGuirk, J., Hamadani, M., & DeWolf, S. (2024). SARS-CoV-2 Vaccination in the First Year After Hematopoietic Cell Transplant or Chimeric Antigen Receptor T-Cell Therapy: A Prospective, Multicenter, Observational Study. Clinical Infectious Diseases, 79(2), 542–554. https://doi.org/10.1093/cid/ciae291

Chicago

Hill, Joshua A, Michael J Martens, Jo-Anne H Young, Kavita Bhavsar, Jianqun Kou, Min Chen, Lik Wee Lee, et al. 2024. “SARS-CoV-2 Vaccination in the First Year After Hematopoietic Cell Transplant or Chimeric Antigen Receptor T-Cell Therapy: A Prospective, Multicenter, Observational Study.” Clinical Infectious Diseases 79 (2): 542–54. doi:10.1093/cid/ciae291.